Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen releases results of Vectibix trial

Amgen releases results of Vectibix trial

9th November 2009

Amgen has unveiled the results of a trial into its metastatic colorectal cancer (mCRC) treatment Vectibix (panitumumab).

The firm revealed that the drug, administered in combination with Folfox (an oxaliplatin-based chemotherapy) as a first-line treatment of mCRC, failed to meet a secondary endpoint of overall survival.

Administering the therapies resulted in a median overall survival of 23.9 months, compared to 19.7 months for patients treated with Folfox alone.

The median overall survival difference of 4.2 months in the Vectibix demographic did not reach statistical significance.

Roger Perlmutter, executive vice-president of research and development at Amgen, commented that although it is not “statistically significant”, the firm is encouraged by the positive data trend of overall survival in Vectibix-treated patients.

In other Amgen news, the firm posted its third-quarter financial results for 2009 last month, revealing adjusted earnings per share of $1.49 (91p) during the timeframe.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.